Location: Solothurn, Switzerland
MAPS is proud to sponsor the first study of the therapeutic use of LSD in humans in over 40 years. This study, based in Switzerland, investigates the safety and effectiveness of LSD-assisted psychotherapy in subjects with life-threatening illnesses and who are experiencing associated anxiety. The study received final approval from the BAG (the Swiss DEA) on December 5, 2007, final approval from the Ethics Committee (the Swiss IRB equivalent) on October 30, 2007, and clearance from SwissMedic (the Swiss FDA equivalent) on November 8, 2007. The first subject was enrolled on April 23, 2008, and all subjects have now been treated. The paper describing the results was published online on March 4, 2014, in the Journal of Nervous and Mental Disease.
- Study protocol
- Results paper published in the Journal of Nervous and Mental Disease (March 2014)
- Qualitative results paper published in the Journal of Psychopharmacology (November 2014)
- LSD Investigator’s Brochure
- Memorandum of Understanding Between MAPS and Dr. Gasser
- Study Timeline